Data from the COMMIT trial demonstrated that the addition of oxaliplatin, leucovorin, 5-fluorouracil (mFOLFOX6) and ...
Colorectal cancer (CRC) remains one of the most prevalent and lethal malignancies worldwide, representing a major challenge ...
Colorectal cancer is the third most common cancer globally, with approximately 1.8 million people diagnosed in 2022 ...
Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were ...
Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating ...
Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 monthsNotable ...
In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for ...
SAN FRANCISCO -- Including encorafenib (Braftovi) and cetuximab (Erbitux) in the first-line treatment of BRAF V600E-mutated ...
A review article led by researchers from the B·ARGO group at the Germans Trias i Pujol Research Institute (IGTP) and from the Medical Oncology Department of the Catalan Institute of Oncology (ICO) in ...
This segment analyzes key limitations of current evidence—including the non-randomized design of PHAROS and challenges of cross-trial comparison—while underscoring the ongoing need for better ...
This segment establishes the clinical context for BRAF V600E–mutant metastatic NSCLC, a relatively rare but clinically important subset of lung cancer. This segment establishes the clinical context ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback